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Genomic Accumulation of Retrotransposons Was Facilitated
1 by Repressive RNA-Binding Proteins: A Hypothesis
2 Jan Attig* and Jernej Ule*
3 Retrotransposon-derived elements (RDEs) can disrupt gene expression, but are
4 nevertheless widespread in metazoan genomes. This review presents a hypothe-
5 sis that repressive RNA-binding proteins (RBPs) facilitated the large-scale
6 accumulation of RDEs. Many RBPs bind RDEs in pre-mRNAs to repress the
7 effects of RDEs on RNA processing, or the formation of inverted repeat RNA
8 structures. RDE-binding RBPs often assemble on extended, multivalent binding
9 sites across the RDE, which ensures repression of cryptic splice or polyA sites.
10 RBPs thereby minimize the effects of RDEs on gene expression, which likely
11 reduces the negative selection against RDEs. While mutations that change splice
12 sites in RDEs act as an off-on switch in exon formation, mutations that decrease
13 the multivalency of RBP binding sites resemble a rheostat that enables a more
14 gradual evolution of new RDE-derived exons. RBPs might also repress aberrant
15 processing of active retrotransposons, thus increasing the chance that full-length
16 copies are made. Taken together, in this review, it is proposed that RBPs facilitate
17 the widespread accumulation of intronic RDEs by repressing RNA processing
18 while chaperoning their potential to gradually evolve into new exons.
19 1. Introduction
20 Retrotransposons use reverse transcriptase to copy themselves
21 within the genome through an RNA intermediate, a process
22 known as retrotransposition. Retrotransposons are present in
23 most eukaryotic genomes, including virtually all knownmamma-
24 lian and plant genomes.[1] Retrotransposon-derived sequences
25 contribute to10.9 and44% of the genomes of Danio rerio and
1Homo sapiens, respectively.[2] Many families
2of retrotransposons have been identified
3across eukaryotic clades (reviewed in
4refs. [1,3]). In the human genome, most
5retrotransposon integrations correspond to
6the long interspersed nuclear elements
7(LINEs), including the L1, L2, and CR1
8subfamilies, the short interspersed nuclear
9elements (SINEs), including the primate-
10specific Alu and SVA elements, and the
11transposons flanked by long-terminal
12repeats (LTRs), including single LTRs and
13endogenous retroviruses (ERVs).
14Here,we develop a framework to describe
15the evolutionary dynamics and consequen-
16ces of retrotransposons for gene expression
17at the level of RNA processing, and the
18protein regulators that bind to them. We
19propose that active retrotransposons and
20their inactive genomic progeny share RNA-
21binding protein (RBP) interaction partners,
22and discuss at which stages selection might
23act on them and how these interactions
24enable retrotransposons to accumulate in
25the genome without disrupting the fitness of the host.
262. Many RNA-Binding Factors Bind
27Retrotransposons to Regulate Their
28Retrotransposition
29Active retrotransposition poses a threat to genomic stability and
30cellular function.[4–6] As a consequence, strong transcriptional
31repressors target active retrotransposon families, as reviewed
32elsewhere.[7] In addition to these DNA-binding proteins, many
33host RBPs bind and regulate retrotransposons. Some of the RBPs
34are co-opted by the retrotransposon and necessary for retro-
35transposition, while other RBPs act as restriction factors of
36retrotransposition. Most interaction partners have to date been
37identified by co-immunoprecipitation with L1 RNPs. L1 encodes
38two ORFs, ORF1p that is an RBP, and ORF2p, which harbors the
39reverse transcriptase domain. For reverse transcription, ORF2p
40uses the polyA tail of the L1, which is annealed as primer:template
41to a DNA insertion site.Many RBPs are interaction partners of L1-
42ORF1p, L1-ORF2p, or the L1-ORF1pORF2p RNP, and a recent
43CRISPR screen for factors affecting L1 retrotransposition
44demonstrated that many of these RBPs have positive or negative
45effects on L1 retrotransposition (refs. [8–11], listed in Figure 1).
46For illustration, we discuss as examples MOV10 and TUT4/7;
47additional restriction factors have already been reviewed in
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1 detail.[7] MOV10 is an ATP-dependent RNA helicase that was
2 first identified as a restriction factor of Moloney leukemia
3 virus.[12] MOV10 interacts with multiple enzymes that act as
4 restriction factors of retrotransposons, including the adenosine
5 deaminase ADAR1, the cytidine deaminase APOBEC3G, and the
6 terminal uridylyltransferases TUT4/TUT7.[13–17] MOV10 inhib-
7 its retrotransposition of all human non-LTR retrotransposons in
8 cultured cells,[18,19] most likely by promoting the activity of these
9 enzymes, for example TUT4/TUT7. When a poly(A) tail is
10 shortened and not protected by poly(A)-binding proteins, TUT4
11 and TUT7 act as terminal uridylyltransferases to promotemRNA
12 decay.[20] In vitro, L1-ORF1p inhibits the access of TUT4/7 and
13 RNases to L1 RNA. MOV10 displaces L1 ORF1p and thus allows
1access of TUT4/7 to L1 RNA to promote its degradation and
2inhibit reverse transcription.[17]
33. Retrotransposon-Derived Elements, or
4RDEs, Are Common in Introns
5The vast majority of insertions of retrotransposons are silent due
6to truncations or accumulation of mutations that inactivate their
7capacity for retrotransposition. For example, >99% of LINEs in
8the human genome contain truncations or mutations that fully
9inactivated their capacity for retrotransposition, and therefore
10can be considered “dead.” We refer to such copies as
11retrotransposon-derived elements, or RDEs, which have lost
Figure 1. Different classes of RBPs interactwith active retrotransposons and retrotransposedgenomic copies. Retrotransposons sequences are transcribed
into RNA in two different scenarios. On the one hand, for active and autonomously transcribed retrotransposons, the RNA transcript is the template for
reverse transcription. On the other hand, past insertions of a retrotransposon in the genome are frequently transcribed as part of another gene, as
retrotransposon-derived element or RDE. A number of RBPs are regulators of retrotransposons, and broadly fall in one of three categories: helicases,
sequence editing enzymes, and sequence-specific RBPs. Identification of RBPs interacting with active retrotransposons has often been done by co-
purification schemes andmass spectrometry.[8–10] Recently, a CRISPRscreenhas revealedmanypositive andnegative regulators of active L1.[11] Screening of
RNA interactome data from crosslinking and immunoprecipitation of RBPs has identified dozens of RBPs that interact with RDEs.[38] A few of the RBPs
that restrict L1 retrotransposition, are well-characterized and general mRNA surveillance factors (MOV10, UPF1, TUT4/7, RNASEH2). For these RBPs it
seems unlikely that they have specificity toward RDE sequences and regulate intronic RDEs beyond their general role in mRNA surveillance.
www.advancedsciencenews.com www.bioessays-journal.com
BioEssays 2019, 1800132 1800132 (2 of 12) © 2019 The Authors. BioEssays Published by Wiley Periodicals, Inc
1 all ability to retrotranspose. While active copies of retrotrans-
2 posons are under negative selection pressure,[21] regulatory
3 evolution of RDEs leads to acquisition of new functions as
4 enhancers, promoters, exons, or polyA sites.[22–24] The acquisi-
5 tion of promoters could be traced to sequence mutations at
6 individual RDEs that took place long after the genomic insertion
7 of the RDE.[25,26] Recent studies made great progress in
8 understanding how the acquisition or loss of binding sites for
9 transcription factors (TFs) and RBPs can be a strong driving
10 force for the regulatory evolution of RDEs.
11 Asaconsequenceof their sheer abundance,over amillionRDEs
12 are transcribed as part of introns within host genes.[3] RDEs often
13 contain cryptic sites for RNA processing, which can perturb gene
14 expression and lead to loss-of-function phenotypes if used in an
15 unregulated manner, a feature that makes them disease
16 alleles.[27,28] BothAlus andLINEscandisrupthost geneexpression
17 when cryptic splice or polyA sites within them are erroneously
18 recognized.[29–31] For instance, newly inserted L1 elements are
19 documented to have caused thalassemia due to disruption ofHBB
20 expression,[32] X-linked retinitis pigmentosa 2 due to disruption of
21 XRP2,[33] chronic granulomatous disease due to disruption of
22 CYBB,[34] and X-linked dilated cardiomyopathy due to disruption
23 of DMD.[35] In these cases, “exonization” of the L1 creates a L1-
24 derived exon within the coding sequence, which introduces
25 premature termination codons (PTCs) that truncate the protein
26 and induce nonsense mediated mRNA decay (NMD). Moreover,
27 polymorphic Alu insertions can also affect splicing of nearby
28 alternative exons. For example, an Alu insertion promotes
29 skipping of an exon in the gene CD58, reduced expression of
30 which is associated with risk for developing multiple sclerosis.[36]
31 Theproportionof intronicRDEsaffectingRNAprocessingatfirst
32 sight seems rather small compared to theoverall numberof intronic
33 RDEs. Yet, the listed examples represent only the known de novo
34 insertions in humanpatients, whereas the vastmajority of genomic
35 RDEsarefixed in thepopulation.With thedeleterious effects ofnew
36 intronic insertions in mind, a question arises: how do RDEs
37 accumulate in introns at such high proportion, and is there some
38 cellular mechanism in place that controls the majority of them?
39 4. Many RBPs Bind to Intronic RDEs to
40 Regulate Their RNA Processing
41 Tens of thousands of intronic RDEs contain cryptic splice sites
42 (Table 1) with the potential to disrupt gene expression, yet few
43 seem to do so. It has become evident that many RBPs recognize
44 specific sequence or structural motifs formed by the different
45 RDE families, and thereby efficiently protect host gene
46 expression by reducing recognition of RNA processing sites
47 within them. Prominent examples of RBP:RDE interactions are
48 discussed here in detail, and include control of Alu RDEs by
49 HNRNPC/U2AF65, ADAR/DHX9 and STAU1/PKR, and re-
50 pression of LINE-derived exons by MATR3/PTBP1.[37–41]
51 4.1. Repression of RNA Processing in Antisense Alus by
52 hnRNPC
53 Most intronic Alu elements are 150–300 nt long. Antisense Alus
54 are prone to exonize,[31,42] and exonization events are associated
1with human diseases.[43] Exonization of sense Alu elements is
2much rarer due to their lack of pyrimidine tracts and 30 splice site
3sequences (Table 1A). Inclusion of Alu-exons frequently
4introduces a PTC, thus targeting the transcript to NMD. Alu
5exonization is widely inhibited by hnRNPC, which binds to the
6U-tracts of antisense Alu elements.[41] In sense orientation, the
7transposing Alu contains an internal A-tract and 30 polyA-tail,
8which is necessary for co-option of LINE ORF2p for retro-
9transposition.[44] Hence, when de novo Alu insertions are
10transcribed in an antisense orientation as part of the host gene,
11they contain two U-tracts. The U-tracts are recognized by
12hnRNPC, which incorporates the Alu sequence into the hnRNP
13particle and thereby blocks its splicing and 30 end process-
14ing.[41,45] However, if mutations disrupt the U-tract to prevent
15binding of hnRNPC, it can turn into a binding site for U2AF65
16and TIA1/TIAL1, the splicing factors that assist in the
17recognition of 30 and 50 splice sites. We have shown that
18U2AF65 and hnRNPC directly compete for binding to U-rich
19motifs in thousands of antisense Alus,[41] and T to C mutations
20favor U2AF65 binding. As a result, there is a close relationship
21between the age of Alu insertions, the length of their U-tracts,
22the relative binding of hnRNPCversus U2AF65, and exonization
23of Alus.[39]
244.2. ADAR/DHX9 and Editing of RNA Duplexes
25When two proximal Alu elements are present within an RNA in
26opposing orientation, they can form double-stranded RNA
27structures (dsRNA) if their complementarity has not been
28disrupted through accumulation of mutations. When such
29inverted repeats are present within 30 UTRs, they can become a
30signal for nuclear retention of the mRNA and its decay in the
31nucleus.[46,47] Moreover, inverted Alu repeats form the most
32common substrate of the RNA editing enzyme ADAR1.[48,49]
33ADAR deaminates adenosine nucleotides to inosines, and
34interacts with DHX9, an RNA helicase.[37] Editing prevents
35formation of double-stranded RNA since inosine pairs with
36cytosine, not uridine, and DHX9 unwinds dsRNA formed by
37Alus. In the absence of DHX9, the Alu-derived secondary
38structures can also disrupt RNA processing. Hence, ADAR1 and
39DHX9 play a similar role as hnRNPC by protecting the
40transcriptome from misprocessing at Alus.
41If inverted Alu repeats are not edited and escape to the
42cytoplasm, they can be recognized by the viral RNA sensor PKR1,
43which can lead to partial and unspecific translational shut-
44down.[50] In mouse, ADAR knockouts are embryonically lethal
45because of an autoimmune phenotype, triggered by MDA5, a
46sensor of viral RNA, that erroneously recognizes endogenous
47RNAs in absence of editing.[51–53] Hence, ADAR is a paradigm
48example of a restriction factor that also plays a vital role on
49control of RDEs within the host genome.
504.3. Repression of LINE Exonization by MATR3 and PTBP1
51LINEs are prone to be spliced both in sense and antisense
52orientation.[29] Since LINEs are much longer sequences
53compared to Alus, more regulators bind to them, and dozens
www.advancedsciencenews.com www.bioessays-journal.com
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1 of RBPs are highly enriched on LINEs.[38] We found a number of
2 RBPs show strong enrichment toward targeting of evolutionarily
3 young LINEs, including MATR3, hnRNPM, and SUGP2. While
4 LINE-binding RBPs likely serve a multitude of functions at
5 RDEs, such as resolving RNA duplexes or anchoring RNAs to the
6 chromatin (discussed in more detail below), it was striking that
7 known splicing repressors formed the majority among the RBPs
8 preferentially recognising evolutionarily young LINEs.
9 This suggested to us that LINEs are pre-marked as intronic
10 sequence at new insertions. We found support for this
11 hypothesis from two angles. Firstly, exons arise about two-times
12 more frequently from evolutionarily old LINEs, and these exons
13 show higher inclusion levels in more tissues, despite compara-
14 ble strength of their splice site sequences. Secondly, MATR3 and
15 PTBP1 were among the most enriched RBPs on intronic LINE
16 sequences, and depletion of both proteins increased inclusion of
17 cryptic exons derived from antisense L1s.[38] Just as the hnRNPC-
18 repressed Alu-exons, inclusion of such cryptic LINE-exons tends
19 to decrease the stability the mRNA isoform through NMD.
20 Hence, LINEs have a high intrinsic propensity to exonize, but are
21 generally efficiently repressed due to the function of RBPs acting
22 in trans. Interestingly, LINEs are excluded in a wide window
23 from established exons both in mouse and man, suggesting that
24 they interfere with splicing of close-by splice sites.[38]
25 4.4. Splice Repressors at ERVs?
26 Due to their LTR promoter structure with a strong 50SS, ERVs are
27 particularly likely to produce splice-fusion transcripts with
28 downstream genes,[54–56] a feature that might create a need to
29 have splice repressors recognizing ERV sequence to reduce the
30 amount of fusion transcripts. However, so far no RBP has been
1described to act on ERV transcripts, neither in the context of an
2ERV RNP particle, nor in the context of insertions transcribed as
3part of a host gene.
45. RBPs Generally Emerged Earlier in Evolution
5Than the Regulated RDEs
6To assess the timing of evolutionary emergence of RDEs and
7their regulators, we performed cross-species analysis of the
8timing of L1 and Alu amplification waves that generated new
9RDEs at bulk, and the primary RBPs that repress them
10(Figure 2), using both orthoDB[57] and ENSEMBL compara.[58]
11RBPs that repress Alus, such as hnRNPC, ADAR and DHX9, are
12conserved between vertebrates and invertebrates, and often their
13RNA-binding domains are almost perfectly conserved across
14these lineages. In contrast, Alu elements are primate-specific.
15Thus, the repressors predate the emergence of intronic Alu
16repeats, and in the mouse ADAR and DHX9 recognize RNA
17duplexes formed from other sources than Alus.[59–62]
18LINE elements are evolutionarily older than Alus. L1 elements
19were hyperactive several times early on inmammalian evolution,
20for instance after the therian clade diversified frommonotremes
21(ref. [63], see also Figure 2). Intronic insertions are bound by
22repressive RBPs, including MATR3, hnRNPM, and the PTBP
23family proteins.[38] According to orthoDB,[57] MATR3 likely
24emerged within an early vertebrate ancestor in the Osteichthyes
25lineage, since no orthologues could be identified in any of the
26other metazoan classes examined (Figure 2). The PTB protein
27family and hnRNPM protein have orthologues in all metazoans
28we investigated (vertebrates and invertebrates). Hence, MATR3,
29PTBP1, and hnRNPM have predated the major amplification
30waves of mammalian L1 elements.
Table 1. Putative splice sites within mammalian RTEs.
(A) Splice site sequences in repeat consensus sequences (B) Cryptic splice sites within retrotransposons in the human genome
# of predicted splice sites in
# of splice sites in
intergenic insertions
# of splice sites in
intragenic insertions
Repeat family Sense [strength] Antisense [strength] Repeat family Sense Antisense Sense Antisense
LIME (L1.3) LINES 697255 289503 435470
50 SS 11 [8.0–8.3] 9 [8.0–10.1] With 5SS 76050 102122 25521 59611
30 SS 45 [8.3–8.7] 25 [10.3–12.6] With 3SS 46392 82808 19079 44299
Alus (AluSx, AluJb) Alus 484786 294626 357352
50 SS 0 [  4.7 to 4.9] 2 [2.4–4.3] With 5SS 55107 12083 33638 7744
30 SS 0 [0.3–0.97] 2 [14.2–6.5] With 3SS 414 198598 252 148172
ERV1 (HERVH) ERVs 439433 102772 178299
50 SS 7 [8.9–10.5] 35 [10.3–10.7] With 5SS 54696 78424 12176 31148
30 SS 43 [10.1–10.8 36 [7.3–9.8] With 3SS 41022 41897 8794 17323
(A) Retrotransposons frequently contain putative splice sites. The number of splices sites and their predicted strength is shown for the major families of human RTEs, with
L1.3, the sequence of AluSx and AluJb, and the HERVH consensus sequence from repbase as examples. The number of putative splice sites was determined with
NetGene2.[99] NetGene2 did not call any of the putative splice sites in Alus, so we used the splice site positions identified by Lev-Maor et al. and Sorek et al. (indicated by ).
Splice site strength was predicted withMaxEntScan,[100] and we summarise the strengths of the TOP3 splice sites. The sequences of the TOP3 splice sites are listed in Table
S1, Supporting Information. Table S1, also lists splice site analysis for mouse LI and the consensus sequence for mammalian L2. The interquartile range of predicted splice
site strengths for constitutive human exons is 6.2–10.0. (B) We show the number of cryptic splice sites within the human genome (assembly hg38) generated through RTE
insertions in sense and antisense. To estimate the number for RTEs with 50 and 30 splice sites, we searched for NNGGURAG and Y8NBAGR sequences, respectively.
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1 From such cross-species comparisons it is clear that in most
2 cases, RBPs are evolutionarily more ancient than the RDEs that
3 they repress. This supports the notion that presence of repressive
4 RBPs could increase the capacity of RDEs to accumulate in
5 introns across the genome through minimising the negative
6 selection against them. It would equally be expected that
7 emerging RDE families with pre-existing repressive RBP
8 partners are more likely to spread in the genome.
9 6. Exons Tend to Emerge From RDEs Through
10 Gradual De-Repression
11 Since the RBPs are evolutionarily older than the RDEs that they
12 repress, repressive RNPs could have assembled on intronic
13 RDEs since their earliest emergence. We have shown that the
1consensus RDE sequences are generally rich in multivalent
2binding sites for repressive RBPs. For instance, antisense Alus
3contain two separate U-tracts that are often >8 nt long, and a U-
4tract of 4 nts is sufficient to accommodate 1RRM domain of
5hnRNPC.[64,65] Thus, Alus with longer U-tracts can accommo-
6date multivalent binding of the four RRM domains of hnRNPC
7(two at each U-tract), leading to high-affinity binding. An even
8more extreme example is the multivalency of the antisense L1
9consensus, which is covered by many dozens of binding motifs
10for PTBP1 and MATR3.[38]
11Neutral evolution leads to deviations in the RDEs from the
12consensus sequence of the founder retrotransposon. As part of
13this process, some mutations will increase the strength of splice
14sites or polyA sites within the RDEs, or position 50 and 30 splice
15sites in a conformation that favors inclusion of a new RDE-
16derived exon into the mRNA product of the gene (Figure 3).
Figure 2. Amplification of RDEs took place in an environment of cognate RNA binding proteins. Phylogenetic comparison of RDE-binding RBPs and known
amplification periods of RDEs in referencemetazoans. The phylogenetic tree is focused on reference organismsofmajor cladeswith increasing evolutionary
distance tohumanandmouse(guidedby ref. [101]).The tree is forvisualizationpurposesonlyandevolutionarydistancesbetweencladesandspecies isnot to
scale. All branches are depicted as accepted in recent literature[101] andmajor clades within the tree are labeled. Disputed groups within the Arthropoda are
shown asmulti-nodes but do not affect the analysis of protein orthologues depicted. Known amplification periods of Alu, L1, and L2 elements aremarked by
hash tags and identified from references.[63,98,102] Kordis et al. established that there was an amplification of L1 elements in the last common ancestor of
vertebrates.We focusexclusively onknownamplificationperiod, since the initial emergenceof LINE families isnot resolved. It remainspossible that L1swere
introduced into a mammalian ancestor through horizontal transfer,[97] instead of being vertically transmitted from the metazoan ancestor. It is worth
mentioning that Nematodes and insects are devoid of L1 and L2 elements, and dominated by other LINE families (RTE, jockey) while the simple chordates
(Strongylocentrotus purpuratus, Branchiostoma floridae, Ciona intestinalis) contain L1 and L2 elements. Orthologues of human RBPs were identified by
orthoDB,[57] which groups proteins if they are likely to originate from a distinct common ancestor. hnRNPC and hnRNPCL are closely related to RALY and
RALYL proteins in all species and form one group with one common ancestor, so do isoforms of the PTBP proteins.
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1 Many RDEs, particularly antisense L1 and Alus, contain
2 sequences that are strong splice sites or are only one base-pair
3 mutation away from the splice site consensus sequence
4 (Table 1, see also refs. [30,38]). If such an RDE inserted but
5 lacks a repressive RBP binding partner, or an existing RDE
6 acquired a mutation creating a strong splice site, that event
7 would likely create an immediately highly included exon
8 (Figure 3A), in effect amounting to a binary on-off switch.
9 However, as we have the shown consensus RDE sequences
10 contain multivalent sequences that are strong binding sites for
11 repressive RBP, and therefore an emerging RNA processing
12 site is likely under direct control of a repressive RBP. In this
13 setting, a novel splice site will first create a cryptic exon that is
14 either not or lowly included into mRNAs (Figure 3B). In
15 addition, RDE consensus sequences in human show a general
16 lack of exonic splice enhancer sequences,[38,66] which could
17 further contribute to low inclusion levels of emerging exons.
18 We have shown that the inclusion level of exons at RDEs
19 correlates with the evolutionary age of the RDE, both for Alu
20 and L1 elements.[38,39] Importantly, changes in splice site
21 sequences and strength distinguished exonising from non-
22 exonising Alus, but did not explain differences in their
23 inclusion levels.[39] Instead, all our findings indicate that upon
24 evolutionary divergence of RTEs, accumulation of mutations
25 tends to gradually decrease the number of multivalent binding
1motifs for repressive RBPs. Given the large number of
2repressive multivalent motifs that are coupled with each
3cryptic splice site, mutations leading to gradual loss of these
4motifs are likely a major factor in controlling exon inclusion
5levels. For instance, gradual shortening of the repressive U-
6tracts at older Alus is accompanied by reduced hnRNPC
7binding and increased inclusion levels.[39] We also found that
8the evolutionarily older RDEs, or RDEs with more sequence
9divergence relative to the RDE consensus, are more accessible
10to RBPs that enhance splicing or 30 end processing (U2AF2,
11TIA1/TIAL1, CSTF2, etc.) and are more likely to contain exonic
12splice enhancer sequences,[38] in agreement with a previous
13study from the Eyras lab.[66] We use the term “regulatory
14evolution” for this process where mutations gradually shift the
15balance from RBPs that repress to those that promote RNA
16processing at RDEs. The mutations in the multivalent binding
17sites could act as a rheostat for regulatory evolution that
18gradually increases the inclusion of RDE-derived exons
19through de-repression.
207. Do Repressive RBPs Promote Evolutionary
21Tinkering at Intronic RDEs?
22Francois Jacob has coined the term “evolutionary tinkering”
23for systems that facilitate evolutionary novelty but are
Figure 3. Co-evolution of splice sites and RBP interaction sites in RDEs controls inclusion of RDE-derived exons. RDEs contain both splice sites and
binding sites for splice-repressive RBPs. Mutations have different outcomes for inclusion of cryptic exons, depending on if splice sites and the repressive
RBPs are coupled or not. The two scenarios are illustrated in (A) and (B), with visualization of exon inclusion levels by exemplary RT-PCR assay images.
A) If they evolve independently, changes in splice site conformations will manifest as a binary switch in inclusion or skipping of an RDE-derived exon. This
includes scenarios where a new RDE has pre-existing functional splice sites (i) or where randommutations happen to increase splice site strength (ii). B)
If splice sites are coupled with splice-repressive proteins, changes to the splice sites determine the capability of the RDE to exonize but inclusion levels
remain low. Multiple mutations in the multivalent binding sites will lead to gradual increase in inclusion. In addition, RDEs often lack exonic splice
enhancer sequences, which can recruit splice-activating RBPs.[66] The need to accumulate those through mutations further reinforces the gradual
emergence of novel exons. Given the random occurence of mutations and position of an emerging RDE-derived exon within transcripts, sudden full
inclusion of a novel exon is likely to result in a fitness cost to the organism. As discussed in the text, both Alu and LINE-derived exons are examples of
scenario (B). Gradual evolution of a novel exon is likely more suited to create variation while maintaining essential gene functions.
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1 self-constrained at their origin, in that they have to maintain
2 pre-existing functions.[67] This concept suits the process
3 leading to the exonization of RDEs across the transcriptome.
4 If RDEs were not initially repressed by RBPs, they would
5 undergo rapid negative selection, and be deleted from the
6 gene pool. Since they are repressed, they can diversify and
7 potentially acquire new functions, which can benefit the
8 population and outweigh the risk of aberrant processing at
9 other RDE insertions of the same family.
10 This risk is likely reduced throughefficient repressionof intronic
11 RDEs.Misprocessing ofRDEs into aberrant exonswould impact on
12 the organism’s fitness or reproduction (Figure 4). RDE-derived
13 exons created through an off-on switch will be most likely removed
14 from the population due to negative selection. Repressive RBPs
15 minimize the likelihood of such a discrete off-on switch and can
16 keep the exons in a cryptic state, thereby minimizing negative
17 selection against the exon and enabling it to persist in the
18 population. We expect that each RDE family attracts its own set of
19 repressiveRBPs,whichhelpedwith the accumulationof theRDE in
20 the genome, which helpedwith the accumulation of the RDE in the
21 genome. Ourmodel could explain the observation that surprisingly
22 many RBPs recognize RDEs in antisense orientation, that is, the
23 reverse complement of the retrotransposal sequence. In particular,
24 we identified many more RBPs that recognize L1 elements in
25 antisense orientation than in sense (Figure 1, see also ref. [38]). The
26 human genome has about twice as many cryptic splice sites in
27 antisenseL1s compared to senseL1s (Table1B). Potentially, reduced
28 negative selection against splice sites in antisense L1s favors
29 accumulationof splice sites inantisenseL1sover those in senseL1s.
30 Due to the capacity of newly created exons to persist in the
31 population in a cryptic, repressed state, gradual accumulation of
32 further mutations can eventually lead to adaptive variation. It has
33 been shown that older RDEs have been increasingly exaptated into
34 regulatory roles.[68] This is consistent with the increased density of
1olderRDEsclose toexons.[38,69]Moreover inclusionofRDE-derived
2alternative exons correlates with their evolutionary age, such that
3both Alu- and LINE-derived exons are included into mRNAs in a
4highly tissue-specific manner, most frequently in the brain and
5testis.[38,39] Thismight be explainedby abias for exonizationwithin
6tissue-specific genes, or regulation of the cognate repressive RBPs.
7For example, PTBP1 is not expressed in the brain though its close
8homologue PTBP2 is, and both hnRNPC and MATR3 contain
9many sites for post-translational modifications, of yet unknown
10function. An alternative reason could be the differential strength of
11selection pressure at different groups of genes during fixation of
12RDEs.Highly expressedgenesare selected for short introns,[70] and
13essential or ubiquitously expressed genes might have stronger
14negativeselectionagainst insertionofRDEs.Conversely,genes that
15evolve quickly typically have tissue-specific functions, such as
16immune tissues or the brain. RDEs could enhance the sequence
17turnover at such genes, and thus be particularly important for
18evolutionary tinkering in tissue-specific functions.
198. Do the Same RBPs Act Both on Active
20Retrotransposons and RDEs?
21Active retrotransposons and their intronic progeny will share the
22same RBP binding sites, if the RDEs are transcribed in sense
23orientation. Hence, we might predict new regulators of intronic
24RDEs from factors that regulate active retrotransposons, and vice
25versa. Reviewing the known interaction partners of Alus and
26LINEs, we find such a dual role well supported for helicases
27(Figure 1), but this principle could extend well to other factors,
28such as splicing repressors.
29The DHX9 and UPF1 helicases are known interaction
30partners of Alus and LINE retrotransposons, among others.[8,10]
31Depletion of DHX9 or UPF1 reduces L1 retrotransposition.[10,11]
Figure 4. The outcome of a newly emerging exon in an RDE depends on the bound RBPs. Any active RTEs will generate new insertions in the genome,
which will be either intergenic or intronic. Intronic RTEs will be transcribed as part of the host gene and exonize if strong splice site sequences are present
in the inserting RTE. Exonization of RTEs is prone to reduce expression level of the host gene, and hence has a probability of negatively affecting an
organism’s fitness. If splice repressors are able to effectively recognize and repress exonization events at novel insertions, an active RTE family will affect
fitness at a lower probability. Thereby, the active RTE family has a higher probability to spread in the population.
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1 Here, helicases are likely needed to remove RBPs and secondary
2 RNA structures ahead of ORF2p during reverse transcription. In
3 a genomic context, DHX9 prevents formation of RNA structures
4 derived from inverted repeat RDEs.[37]
5 Another co-factor of retrotransposons are poly(A) binding
6 proteins PABPC1 and PABPN1 (PABP2), which bind to the
7 polyA-tail of L1 RNA and promote retrotransposition.[71] The
8 polyA-tail of L1 and Alus is crucial for retrotransposition   it
9 increases RNA stability, pairs with T4 single-strand overhang
10 during target site-primed reverse transcription, and ORF2p has a
11 preference for binding to A-tails.[72] As a result of the need for a
12 polyA tail, LINE RDEs are particularly rich in polyA signals,[73,74]
13 and we expect they need to be repressed in most of them.
14 PABPN1 has been shown to inhibit cryptic or premature polyA
15 sites in the genome,[75] but it is not known if any such sites derive
16 from LINE RDEs.
17 Finally, nucleolin and SAFB proteins are co-factors of L1, and
18 depletion of either protein reduces retrotransposition.[11,76] At
19 the same time, they also act on nuclear scaffold RNAs derived
20 from or rich in L1 sequence.[77,78] Nucleolin is a ribosome
21 biogenesis factor, and a scaffold component of the nucleolus.
22 Peddigari et al.[76] found nucleolin binds to the inter-ORF spacer
23 of mouse L1, and L1 ORF1p interacts and co-localizes with
24 fibrillarin,[8] another core component of the nucleolus. Hence,
25 the nucleolus plays an as yet undefined role in the L1
26 retrotransposition cycle. On top, L1-containing RNAs appear
27 to act as scaffold lncRNAs to recruit nucleolin and the
28 transcriptional repressor KAP1 in mouse ES cells, to binding
29 sites important for maintenance of the ES cell transcriptional
30 profile.[78] SAFB, SAFB2, and hnRNPU (also called SAF-A) likely
31 have a similar function in bridging nuclear L1-lncRNAs and
32 transcriptional control. The SAF proteins were identified as
33 nuclear attachment factors, and the DNA-binding SAF-Box
34 domain.[79] Past work has indicated that SAF-Box proteins are
35 scaffolds that link nuclear RNA and active chromatin
36 domains,[80] and a dominant-negative mutant of the SAFB
37 interacting partner hnRNPU (also called SAF-A) leads to
38 dissociation of LINE RDE-containing RNAs from euchroma-
39 tin.[77] While the precise molecular mechanisms by which
40 hnRNPU/SAFB/SAFB2 complexes regulate the nuclear fate of
41 LINE RDE-containing RNAs remains unclear, the SAF-box
42 proteins are RBPs that again act on active L1 RNP, as well as L1-
43 RDE containing RNAs. It is worth highlighting that both in the
44 work of Percharde et al.[78] and of Hall et al.,[77] the precise
45 sequence and locus of the RNA transcripts remains elusive, but
46 both indicate a pool of highly transcribed lncRNAs that are either
47 L1-derived, or rich in L1 RDEs.
48 9. Could Repressive RBPs Influence the
49 Efficiency of Active Retrotransposition?
50 Active L1 retrotransposons in human are replete with cryptic
51 splice and polyA sites.[29,74] Belancio et al.[29] have shown that
52 splicing of an active, human L1 elements results in loss of
53 ORF2p sequence and integration of truncated daughter
54 elements that are dead-on-arrival. Hence, long retrotransposon
55 RNA is vulnerable if splicing precedes the formation of the
56 reverse transcriptase complex, and thus it would benefit from
1recruiting splice-repressive proteins. We hypothesize that the
2binding of repressive RBPs might be required to repress the
3splice and polyA sites in long retrotransposons, thus increasing
4the chance that they make full-length copies of themselves
5(Figure 5).
6Just like active LINEs, the RNA transcript of the full ERV
7element including the LTRs (called genomic RNA) can only
8remain active if it remains unspliced until reverse transcription.
9RBPs binding ERVs are not yet known, but it is likely that specific
10repressive RBPs act to inhibit splice sites within ERVs. For HIV,
11SR proteins extensively regulate splicing of the genomic RNA. A
12change in the abundance of several SR proteins decreased the
13amount of infectious HIV particles in vitro.[81,82] This is likely a
14result of changing the ratio of spliced versus genomic RNA, and
15consequently the ratio of viral proteins. By extrapolation, splicing
16repression of ERVs might similarly increase the efficiency of
17their retrotransposition.
1810. How to Test the Hypothetical Role of RBPs
19in the Genomic Accumulation of RDEs?
20We propose that repressive RBPs have facilitated the spread of
21RDEs in metazoan genomes through a combination of two
22factors: by reducing the negative selection against intronic REs,
23and by facilitating retrotransposition of full-length retrotranspo-
24sons. We expect that an active retrotransposon would invade the
25genome at a reduced rate in the absence of the cognate RDE. A
26possible experiment to test thismodel could involve expression of
27theRBPincells of a speciesnaturallydevoidof it, butwithanactive
28cognate retrotransposon. However, no such species is known to
29date, since we find that the RBPs appear to have emerged in
30evolutionearlier than their cognateRDEs (Figure5).Nevertheless,
31it is possible that the RBP binding partners of LINEs co-evolved,
32and that clade-specific properties of RNPs contribute to efficient
33repression of subfamilies of LINE retrotransposons. Therefore,
34one could infect for instance a chicken cell line with a mammal-
35specific L1 family, to test if the trans-acting RBPs in chicken are
36less efficient in promoting the accumulation of the mammalian
37L1. Another approach is creating knockout cells of an RBP-of-
38interest, and testing the retrotransposition rate of L1. Here, one
39would need to keep in mind the other functions of each RBP,
40which might affect the knockout cells capacity for long-term
41propagation. Instead we suggest exploiting synthetic L1s, which
42have been established to monitor the rate of retrotransposition
43and recovery of insertion sites.[83,84] These synthetic L1 sequences
44could be designed to lack the binding sites of repressive RBPs,
45hence allowing them to be tested for their role in retrotranspo-
46sition. The effect of the RBP depletion on new insertions could
47then be measured after a few dozen cell divisions.
48The regulation of RDEs has been studied almost exclusively in
49human cells, hence limiting the inferences that we can make
50about co-evolution of their sequence with their cellular
51environment. We need to learn more about the impact of RDEs
52on gene expression in other genomes, such as Drosophila and
53monotremes. Here, LINEs are particularly interesting because
54they are present across vertebrates, but different families of LINE
55elements dominate the genomes of different lineages, and
56similar retrotransposon families are present across arthropoda.
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1 If different families of RDEs are kept in check in these species by
2 the orthologues of the human RBPs, then these independently
3 evolved families all contain the binding sites of some shared
4 RBPs, it would provide further support for our hypothesis of the
5 importance of splice-repressive RBPs in regulating retrotrans-
6 posons. An example of a shared role of an RBP is the capacity of
7 DHX9 to resolve inverted repeat sequences formed by Alus in
8 human cells, and by the structurally related B2 elements in
9 mouse cells. Many RDEs contain U-rich motifs in one of their
10 orientations, which can be bound by a number of RBPs,
11 including hnRNPC, MATR3 and PTBP1, and could thus act as a
12 shared sequence feature. Experimental studies of these RBPs in
13 non-mammalian species will be required to understand if their
14 roles in RDE control are more ancient than so far anticipated.
15 This would open the avenue for further comparisons of the
16 adaptive evolution of diverse RDE families, and the sequences
17 that enable their regulation by RBPs.
18 11. Similarities in the Evolution of DNA- and
19 RNA-Binding Sites Within RDEs
20 Actively amplifying RDEs are kept in control by transcriptional
21 silencing, primarily through recognition by the KRAB family of
22 zincfinger transcription factors andpiRNAs.Retrotransposition is
23 effectively limited to the germline in many organisms, and it has
24 beenargued this ismutually beneficial: somatic transpositiondoes
25 notpropagate the retrotransposon to thenextgeneration,butcould
26 be lethal to the host. Hence, there is an equilibrium with the host
27 repressing retrotransposon transcription globally versus selective
28 escape by the retrotransposons targeting the germline. This
29 dynamic is best embodied in Drosophila, where the I-element
30 retrotransposon propagates via the oocyte nursing cells,[85] which
31 effectively excludes anyfitness cost to the individuumitself; aswell
32 as themammalian testis, inwhichactivationof IAVelements in the
33 male mouse occurs in spermatogonia.[86]
34 While piRNAs are changeable at the sequence level to adapt to
35 novel transposon families, the relationship between KRAB
36 transcription factors and their cognate RDE has significant
37 parallels to the dynamics we propose for RDE:RBP interactions.
38 KRAB transcription factors recruit the KAP1 transcriptional
1repressor to a number of retrotransposons families, and
2depletion of KAP1 activates their transcription.[87–89] The KRAB
3family of genes appears to co-evolve with newly arising active
4elements in each evolutionary lineage, as evident by the
5increased number of the KRAB family of genes in parallel with
6amplification of retrotransposons in mammalian genomes.[90,91]
7Similar to the evolution of RBP binding sites within
8transcribed RDEs, regulatory evolution also shapes the land-
9scape of transcription factor binding sites within RDEs. RDEs in
10vicinity of promoters and enhancers and recruitment of a KRAB
11protein can lead to repression of the close-by gene.[92] It has been
12proposed early on that this seeds transcriptional modules in the
13genome.[93] Indeed some KRAB proteins do no longer target
14active retrotransposons but exclusively inactive RDEs, are
15expressed in a tissue-specific manner themselves, and control
16transcription of target genes through RDE-binding.[94] At the
17level of transcriptional control, multiple enhancers and
18promoters mirror in part the multivalent binding sites within
19RNA   again, a combinatorial regulation confers robust-
20ness,[95,96] and can ensure gradual incorporation of novel,
21functional binding sites into an existing promoter structure.
22Comparisons of sequence mutation rate and activity of
23evolutionarily young transcription start sites showed that, while
24they mutate quite quickly, their activity and inclusion as
25regulatory elements is gradual.[26] Hence, new RDEs have
26similar features at the level of DNA and RNA binding sites  
27initial strong repression allows accumulation of new, but
28silenced genetic elements, while step-wise derepression allows
29gradual evolution of functionally important elements.
3012. Conclusion and Outlook
31Most RDEs contain cryptic splice sites and polyA sites, in both the
32sense and antisense orientation, but the potentially disruptive
33inclusion of RDE-derived exons into host transcripts is mitigated
34by repressive RBPs. We present the hypothesis that RDE:RBP
35interactions are beneficial for the host to protect transcriptome
36integrity, but also to the retrotransposon tomaintain its full-length
37retrotransposition and to minimize negative selection against
38RDEs. A key feature of thismodel is that the repressiveRBPsmust
Figure 5. Splicing repressors could promote full-length retrotransposition. Any retrotransposon relies on generating full-length transcripts to copy itself
faithfully at the insertion site. Active LINEs can undergo splicing.[29] This generates shortened LINE transcripts, some of which can still insert into the
genome but then are “dead on arrival,” that is, can not seed further amplification. This could be prevented by splicing repressors, which thereby would
contribute to survival of active retrotransposing elements.
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1 evolutionarily predate the emergence of the retrotransposons, and
2 be able to recognize new insertion sites based on the sequence
3 features of the active retrotransposon. Our analysis of LINE and
4 Alu retrotransposons confirmed this to be the case for the most
5 abundant retrotransposons in mammals.
6 The rapid accumulation of genomic data from many
7 individuals and species will be an excellent resource to further
8 analyse how the mutation rate at RDEs shapes variations in gene
9 expression. So far, most studies have focused on mechanisms
10 involving piRNAs, TFs, and RBPs that restrict retrotransposi-
11 tion.[7,16] More work is needed to understand the complexity of
12 regulatory forces that shape the gradual evolution of RDEs
13 toward functional elements that contribute to the regulation and
14 expression of the host genes.
15 Abbreviations
16 LINE, retrotransposons of the long interspersed nuclear element family;
17 LTR, retrotransposon family flanked by long terminal repeats; NMD,
18 nonsense mediated mRNA decay; RBP, RNA-binding protein; RDE,
19 retrotransposed element, the sequence from past retrotransposon
20 insertions; SINE, retrotransposons of the short interspersed nuclear
21 element family; TF, transcription factor.
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